文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

单倍体外周血干细胞联合骨髓或无关脐带血作为血液系统恶性肿瘤移植物的开放标签、多中心、随机、3期试验

Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological malignancies: an open-label, multicentre, randomised, phase 3 trial.
PubMed 文献 · Lancet Haematol · 2025-02-04

在中国7家医院开展的开放标签随机3期试验中,314例血液系统恶性肿瘤患者随机接受单倍体外周血干细胞联合无关脐带血或联合骨髓移植。联合脐带血组1年无病生存率为82.2%,联合骨髓组为65.6%(HR 0.47,95%CI 0.30-0.74;p=0.0010),且安全性更满意。

要点

  • 联合脐带血组1年无病生存率82.2%,联合骨髓组65.6%,HR 0.47(95%CI 0.30-0.74;p=0.0010)。
  • 移植后100天内3-5级感染发生率联合脐带血组37% vs 联合骨髓组49%(p=0.030)。
  • 移植相关死亡联合脐带血组7例(4%)vs 联合骨髓组17例(11%)。

核心结论

  • 单倍体外周血干细胞联合无关脐带血移植较联合骨髓移植在血液系统恶性肿瘤患者中取得更优的1年无病生存率,安全性更满意。
  • 作者认为,单倍体外周血干细胞联合无关脐带血而非骨髓可能是该人群更好的治疗选择。

研究设计与样本

  • 开放标签、多中心、随机、3期试验,在中国7家医院开展。
  • 纳入18-65岁、诊断为血液系统恶性肿瘤、ECOG体能状态0-2、移植合并症指数0-2且接受首次异基因造血干细胞移植的患者。
  • 314例患者按1:1随机分配至单倍体外周血干细胞联合无关脐带血组(n=157)或单倍体外周血干细胞联合骨髓组(n=157)。
  • 主要终点为1年无病生存率,所有疗效和安全性终点在意向性治疗人群中评估。
  • 试验注册号ClinicalTrials.gov NCT05290545,已完成。

主要发现

  • 2022年3月5日至2023年1月2日筛查357例,314例随机分配;随机分配后中位随访17.2个月(IQR 10.0-20.8)。
  • 1年无病生存率联合脐带血组82.2%(95%CI 75.2-87.3)vs 联合骨髓组65.6%(95%CI 57.6-72.5),HR 0.47(95%CI 0.30-0.74;p=0.0010)。
  • 移植后100天内最常见3-5级不良事件:感染联合脐带血组58例(37%)vs 联合骨髓组77例(49%)(p=0.030);急性移植物抗宿主病49例(31%)vs 61例(39%);胃肠道疾病38例(24%)vs 38例(24%)。
  • 移植后100天内移植相关死亡:联合脐带血组7例(4%)vs 联合骨髓组17例(11%)。
  • 死亡原因(联合脐带血组 vs 联合骨髓组):感染4例(3%)vs 11例(7%);急性移植物抗宿主病1例(1%)vs 3例(2%);血管疾病2例(1%)vs 1例(1%);心脏疾病0例 vs 1例(1%);呼吸系统疾病0例 vs 1例(1%)。

临床怎么用

  • 作者认为,单倍体外周血干细胞联合无关脐带血而非骨髓可能是该人群更好的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Retrospective studies suggested that haploidentical transplantation combined with unrelated cord blood might improve survival for patients with haematological malignancies. We aimed to assess whether transplantation of haploidentical peripheral blood stem cells (PBSCs) plus unrelated cord blood would achieve superior disease-free survival compared with transplantation of haploidentical PBSCs plus bone marrow in this population. METHODS: We did an open-label, randomised, phase 3 trial at seven hospitals in China. Eligible patients (aged 18-65 years) had a diagnosis of haematological malignancy, an Eastern Cooperative Oncology Group performance status of 0-2 and transplant comorbidity index of 0-2, and were receiving their first allogenic haematopoietic stem cell transplant. Patients were randomly assigned (1:1) to receive transplantation of haploidentical PBSCs plus bone marrow or haploidentical PBSCs plus unrelated cord blood. The primary endpoint was 1-year disease-free survival. All efficacy and safety endpoints were assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT05290545) and is complete. FINDINGS: Between March 5, 2022, and Jan 2, 2023, 357 participants were screened for eligibility, and 314 were randomly assigned to receive transplantation of haploidentical PBSCs plus unrelated cord blood (n=157) or haploidentical PBSCs plus bone marrow (n=157). Median follow-up was 17·2 months (IQR 10·0-20·8) after random assignment. 1-year disease-free survival was 82·2% (95% CI 75·2-87·3) in the group receiving haploidentical PBSCs plus unrelated cord blood (PBSCs plus unrelated cord blood group) and 65·6% (57·6-72·5) in the group receiving haploidentical PBSCs plus bone marrow ([PBSCs plus bone marrow group] hazard ratio [HR] 0·47, 95% CI 0·30-0·74; p=0·0010). The most common grade 3-5 adverse events within 100 days of transplantation in participants in the PBSCs plus unrelated cord blood and PBSCs plus bone marrow groups were infections (58 [37%] of 157 vs 77 [49%] of 157, p=0·030), acute graft-versus-host disease (49 [31%] vs 61 [39%]), and gastrointestinal disorders (38 [24%] vs 38 [24%]). Seven (4%) patients in the PBSCs plus unrelated cord blood group and 17 (11%) in the PBSCs plus bone marrow group died of transplantation-related causes within 100 days of transplantation. Causes of deaths in the PBSCs plus unrelated cord blood group versus the PBSCs plus bone marrow group included infections (four [3%] vs 11 [7%]), acute graft-versus-host disease (one [1%] vs three [2%]), vascular disorders (two [1%] vs one [1%]), cardiac disorders (none vs one [1%]), and respiratory disorders (none vs one [1%]). INTERPRETATION: Transplantation of haploidentical PBSCs plus unrelated cord blood achieved superior 1-year disease-free survival compared with transplantation of haploidentical PBSCs plus bone marrow in patients with haematological malignancies, with a more satisfactory safety profile. Our results suggest that combining haploidentical PBSCs with unrelated cord blood, rather than with bone marrow, could be a better treatment option for this population. FUNDING: None.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Yu S, Huang F, Xu N, et al. Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological malignancies: an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2025. PMID: 39919775. doi:10.1016/S2352-3026(24)00372-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。